Law360, New York (January 25, 2013, 6:46 PM EST) -- The Food and Drug Administration announced Friday that it has approved the first over-the-counter treatment for overactive bladder in women, a transdermal patch marketed by Merck, two months after an advisory panel voted against making the treatment available without a prescription because of safety concerns.
Marketed as Oxytrol for Women, the oxybutynin patch treats overactive bladder by relaxing the bladder muscle, the FDA said in its announcement. Some 33 million Americans, most of them older women, have overactive bladder, the FDA said.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.